Karnofsky performance status \>50 or World Health Organization performance score \< 2
primary or recurrence ovarian, peritoneal or fallopian tube epithelial cancer; first intra-abdominal recurrence without distant metastasis (including: unique resectable pleural metastasis which are platinum-sensitive; resectable single lymphatic metastasis retroperitoneal or inguinal)
preoperative platinum-based chemotherapy (carboplatin and paclitaxel, carboplatin and liposomal doxorubicin, gemcitabine, trabectedin or topotecan)
lesion can be removed completely or residual disease \< 0.5 cm
last chemotherapy finished no more than 12 weeks after surgery
no hepatic function damage
white blood cell count ≥3.5\*10\^9/L; platelet count ≥80\*10\^9/L; Hemoglobin ≥90g/L
no contraindication of surgery and anesthesia
life expectancy ≥ 3 months
informed consent form signed
You may not be if
age \< 18 or \>75
no history of other cancer
platinum allergy
distant metastasis
used anti-angiogenic drug within 8 weeks
possibility of more than two resection of alimentary canal
recurrence \< 6 months after primary treatment
histologic type: non epithelial origin
infection out of control
follow-up unable to carry on (geographic or psychic)
cardiac insufficiency or respiratory insufficiency
has received HIPEC already
being in other clinical study
pregnancy or lactation period
Clareo Health | A Randomized Prospective Trail of HIPEC in Recurrent Ovarian Cancer Patients With HRR Mutation
